Bayer 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Bill Anderson

최고 경영자

€11.8m

총 보상

CEO 급여 비율	14.3%
CEO 임기	1.6yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Bill Anderson 의 보수는 Bayer 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-€880m
Jun 30 2024	n/a	n/a	-€1b
Mar 31 2024	n/a	n/a	-€3b
Dec 31 2023	€12m	€2m	-€3b

보상 대 시장: Bill 의 총 보상 ($USD 12.50M )은 Swiss 시장( $USD 4.76M ).

보상과 수익: Bill 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Bill Anderson (58 yo)

1.6yrs

테뉴어

€11,804,104

보상

Mr. William N. Anderson, also known as Bill, is Member of Management Board of Bayer Aktiengesellschaft from April 1, 2023 and also serves as its Chairman of the Management Board and Chief Executive Officer...

리더십 팀

이름	위치	테뉴어	보상	소유권
William Anderson	Chairman of the Management Board & CEO	1.6yrs	€11.80m	데이터 없음
Wolfgang Nickl	CFO & Member of Management Board	6.6yrs	€3.42m	데이터 없음
Stefan Oelrich	Head of the Pharmaceuticals Division & Member of the Board of Management	6yrs	€3.43m	데이터 없음
Rodrigo Santos	Member of Management Board & President of the Crop Science Division	2.8yrs	€3.65m	데이터 없음
Heike Prinz	Chief Talent Officer	1.2yrs	€2.53m	데이터 없음
Julio Triana	Member of Management Board & President of Consumer Health Division	less than a year	데이터 없음	데이터 없음
Sebastian Guth	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
Amanda McClerren	Chief Information Officer	less than a year	데이터 없음	데이터 없음
Jost Reinhard	Head of Investor Relations	1.1yrs	데이터 없음	데이터 없음
Thomas Laubert	Head of Law	1.3yrs	데이터 없음	데이터 없음
Michael Preuss	Head of Communications	8.5yrs	데이터 없음	데이터 없음
Bernd-Peter Bier	Head of Group Finance	no data	데이터 없음	데이터 없음

1.3yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: BAYN 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Paul M. Achleitner	Member of Supervisory Board	22.6yrs	€225.00k	데이터 없음
Ertharin Cousin	Independent Member of the Supervisory Board	5.1yrs	€270.00k	데이터 없음
Heinz Webers	Employee Representative Member of Supervisory Board	2.6yrs	€205.00k	데이터 없음
Simone Bagel-Trah	Independent Member of Supervisory Board	10.6yrs	€227.00k	데이터 없음
Daniel Hartert	Chairman of Executive Board - Bayer Business Services	no data	데이터 없음	데이터 없음
Lori Schechter	Independent Supervisory Board Member	less than a year	데이터 없음	데이터 없음
Horst Baier	Independent Member of Supervisory Board	4.6yrs	€333.00k	데이터 없음
Heike Hausfeld	Vice Chairwoman of Supervisory Board	7.6yrs	€346.00k	데이터 없음
André van Broich	Member of Supervisory Board	12.6yrs	€271.00k	데이터 없음
Otmar Wiestler	Independent Member of Supervisory Board	10.1yrs	€237.00k	데이터 없음
Norbert Winkeljohann	Independent Chairman of Supervisory Board	6.5yrs	€509.00k	데이터 없음
Gunter Hilken	Chairman of Executive Board - Currenta	no data	데이터 없음	데이터 없음

7.0yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: BAYN 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

Bayer 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer AG Announces Management Changes

Recent updates

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Third quarter 2024 earnings released: €4.26 loss per share (vs €4.65 loss in 3Q 2023)

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023)

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

New major risk - Share price stability

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings released: EPS: €2.04 (vs €2.22 in 1Q 2023)

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Full year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022)

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Now 54% undervalued after recent price drop

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Now 38% undervalued after recent price drop

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Now 44% undervalued after recent price drop

Now 45% undervalued after recent price drop

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Now 64% undervalued after recent price drop

Bayer Announces Pharmacodynamic Data on Kerendia

Investor sentiment deteriorates as stock falls 66%

Investor sentiment deteriorates as stock falls 66%

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Investor sentiment deteriorates as stock falls 66%

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Investor sentiment deteriorates as stock falls 66%

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

Investor sentiment deteriorates as stock falls 66%

Now 55% undervalued after recent price drop

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 66%

Now 44% undervalued after recent price drop

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Bayer Initiates Phase III Studies with Investigational Compound Agent Gadoquatrane

FDA Approves Bayer's Ultravist® (iopromide) Injection for contrast-enhanced Mammography

Bayer to Investigate Finerenone in Phase Iii Study in Adults with Chronic Kidney Disease Associated with Type 1 Diabetes

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령